We caught up with Dr. Peter Bossuyt (Imelda General Hospital, Bonheiden, Belgium) to discuss the post hoc analysis of the ADVANCE, MOTIVATE, and FORTIFY studies which investigated risankizumab therapy by baseline Crohn’s Disease location.
The abstract ‘Efficacy of risankizumab induction and maintenance therapy by baseline Crohn’s Disease location: Post hoc analysis of the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies’ (Presentation no. OP40) was presented at the 17th Congress of ECCO, February 16-19, 2022!
- How does disease location affect treatment outcomes in Crohn’s disease? (0:13)
- Could you give us a brief overview of the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies and their findings? (0:56)
- What was the rationale for the current post-hoc analysis of these study data? (2:00)
- What were the findings of the analysis? (3:14)
- How will these findings impact on the future clinical use of risankizumab in patients with Crohn’s disease? (4:58)
Disclosures: Peter Bossuyt discloses receiving financial support for research from AbbVie, Amgen, Janssen, Mundipharma, Mylan, and Pfizer; lecture fees from AbbVie, Celltrion, Janssen, Pfizer, and Takeda; and advisory board fees from AbbVie, Arena pharmaceuticals, Bristol Myers Squibb, Hospira, Janssen, Lilly, Merck, Mundipharma, Pentax Medical, Pfizer, PSI CRO, Roche, Sandoz, and Takeda.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ECCO-IBD virtual meeting 2022.
Share this Video
Related Videos In Digestive Disorders
UEG Young Talent Group – aims, key achievements and opportunities for early career gastroenterologists: Pilar Acedo
The UEG Young Talent Group (YTG) encourages young gastroenterologists to develop their careers through education, networking and training. We were delighted to catch up with UEG YTG Chair Dr. Pilar Acedo to discuss the training, education and professional opportunities available to young digestive healthcare specialists through UEG, the aims and key achievements of the UEG […]
Highlights from Digestive Disease Week 2023: Gil Y. Melmed
Digestive Disease Week took place between 6-9 May, in this touchIMMUNOLOGY interview, we caught up with our Expert Faculty member Prof. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) around his personal highlights from this year’s conference including non-pivotal clinical trial data analysing established inflammatory bowel disease (IBD) therapies such as vedolizumab, data around the […]
Comparison study of upadacitinib and tofacitinib as induction treatment in ulcerative colitis: Gil Y. Melmed, DDW 2023
Upadacitinib and tofacitinib are both JAK inhibitors (JAKis) approved by the FDA for the treatment of ulcerative colitis. In this interview with Expert Faculty member Prof. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) we discuss the aims, design and findings from his study presented at DDW 2023, comparing the efficacy and safety of these […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!